Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-06-12
2008-10-28
Tate, Christopher (Department: 1654)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C514S012200
Reexamination Certificate
active
07442524
ABSTRACT:
Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
REFERENCES:
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5041376 (1991-08-01), Gething et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5180583 (1993-01-01), Hedner
patent: 5225537 (1993-07-01), Foster
patent: 5258288 (1993-11-01), Wydro et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5460950 (1995-10-01), Barr et al.
patent: 5504064 (1996-04-01), Morrisey et al.
patent: 5516640 (1996-05-01), Watanabe et al.
patent: 5580560 (1996-12-01), Nicolaisen et al.
patent: 5648254 (1997-07-01), Mulvihill et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824634 (1998-10-01), Merchant
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5837843 (1998-11-01), Smirnov et al.
patent: 5847085 (1998-12-01), Esmon et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5891843 (1999-04-01), Turecek et al.
patent: 5965425 (1999-10-01), Barr et al.
patent: 5986079 (1999-11-01), Barr et al.
patent: 6013620 (2000-01-01), Turecek et al.
patent: 6017882 (2000-01-01), Nelsestuen
patent: 6100061 (2000-08-01), Reiter et al.
patent: 6423826 (2002-07-01), Nelsestuen et al.
patent: 6475725 (2002-11-01), Reiter et al.
patent: 6693075 (2004-02-01), Nelsestuen
patent: 6747003 (2004-06-01), Nelsestuen
patent: 6762286 (2004-07-01), Nelsestuen
patent: 6806063 (2004-10-01), Pedersen et al.
patent: 6903069 (2005-06-01), Pingel et al.
patent: 7026524 (2006-04-01), Persson et al.
patent: 7220837 (2007-05-01), Nelsestuen
patent: 2003/0100506 (2003-05-01), Nelsestuen
patent: 2003/0100740 (2003-05-01), Persson et al.
patent: 2003/0104978 (2003-06-01), Persson et al.
patent: 2003/0211094 (2003-11-01), Nelsestuen
patent: 2003/0211460 (2003-11-01), Nelsestuen
patent: 2005/0164932 (2005-07-01), Haaning
patent: 2006/0019336 (2006-01-01), Pedersen
patent: 2006/0111282 (2006-05-01), Haaning
patent: 2006/0166874 (2006-07-01), Haaning
patent: 2006/0228782 (2006-10-01), Pedersen
patent: 2006/0240524 (2006-10-01), Petersen
patent: 2006/0240525 (2006-10-01), Pedersen
patent: 2006/0240526 (2006-10-01), Haaning
patent: 2006/0241041 (2006-10-01), Haaning
patent: 2006/0252127 (2006-11-01), Pedersen
patent: 2006/0252128 (2006-11-01), Haaning
patent: 2006/0252689 (2006-11-01), Pedersen
patent: 2006/0252690 (2006-11-01), Pedersen
patent: 2006/0258585 (2006-11-01), Pedersen
patent: 2006/0270000 (2006-11-01), Haaning
patent: 2006/0270001 (2006-11-01), Haaning
patent: 2006/0270002 (2006-11-01), Haaning
patent: 2006/0276377 (2006-12-01), Haaning
patent: 2007/0054366 (2007-03-01), Andersen
patent: 2007/0117756 (2007-05-01), Haaning
patent: 2007/0142280 (2007-06-01), Pedersen
patent: 0 296 413 (1988-12-01), None
patent: 0 354 504 (1990-02-01), None
patent: 0 370 205 (1990-05-01), None
patent: 0 512 011 (1992-11-01), None
patent: WO 88/10295 (1988-12-01), None
patent: WO 91/11514 (1991-08-01), None
patent: WO 92/15686 (1992-09-01), None
patent: WO 94/27631 (1994-12-01), None
patent: WO 96/00577 (1996-01-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 98/35026 (1998-08-01), None
patent: WO 99/03498 (1999-01-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/20767 (1999-04-01), None
patent: WO 99/66031 (1999-12-01), None
patent: WO 00/26230 (2000-05-01), None
patent: WO 00/26354 (2000-05-01), None
patent: WO 00/28065 (2000-05-01), None
patent: WO 00/54787 (2000-09-01), None
patent: WO 00/66753 (2000-11-01), None
patent: WO 01/83725 (2001-11-01), None
patent: WO 02/02764 (2002-01-01), None
patent: WO 02/03075 (2002-01-01), None
patent: WO 02/22776 (2002-03-01), None
patent: WO 02/38162 (2002-05-01), None
patent: WO 03/093465 (2003-11-01), None
patent: WO 2004/029091 (2004-04-01), None
patent: WO 2004/083361 (2004-09-01), None
J. Toomey et al., Localization of the Human Tissue Factor Recognition Determinant of Human Factor VIIa,J. Biol. Chem.266(29):19198-19202 (1991).
Harvey, Stephen B., et al., “Mutagenesis of the y-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site,” The Journal of Biological Chemistry 278(10):8363-8369 (Mar. 2003).
Henderson, Nicole et al., “Response of factor VII and IX-deficient blood to wild type and high membrane affinity mutant factor VIIa in an in vitro whole blood clotting assay: possible correlation to clinical outcome,” Thromb Haemost 88:98-103 (2002).
Stone, Matthew et al., “Unusual benefits of macromolecular shielding by polyethylene glycol for reactions at the diffusional limit: the case of factor VIIai and tissue factor,” Biochemistry 41:15820-15825 (2002).
Zhang, Li et al., “The contributions of individual y-carboxyglutamic acid residues in the calcium-dependent binding of recombinant human protein c to acidic phospholipid vesicles,” The Journal of Biological Chemistry 268 (16):12040-12045 (Jun. 1993).
U.S. Appl. No. 11/279,541, Pedersen et al., Unpublished.
Cheung, W.F. et al., “Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX”,Thrombosis Research, 80(5):419-427 (1995).
Database EMBL, “Gallus gallus anticoagulant protein C precursor (PROC) mRNA, complete cds”, Database Accession No. AF465270, Feb. 2, 2003.
Hedner, U. “NovoSeven as a universal haemostatic agent.”Blood Coagul. Fibrinolysis11 Suppl 1:S107-S111 (2000).
Higashi, S. et al. “Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity,”J. Biol. Chem. 271(43):26569-74 (1996).
Iakhiaev, A. et al. “The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor”,Thromb. Haemost. 85(3):458-463 (2001).
Sorensen, B.B. et al. “Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor,”J. Biol. Chem. 272(18):11863-11868 (1997).
Sridhara S. et al. “Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor,”Am. J. Hematol. 53(2):66-71 (1996).
Zhang E, et al. “Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutan”. J. Mo.l Biol. 1999;285(5):2089-2104.
Database Uniprot “Coalgulation Factor VII (EC 3.4.21.21) (Serum prothrombin converstion accelerator)”, Database Accession No. P22457 Aug. 1, 1991.
Bharadwaj, D., et al., “Factor VII Central—A Novel Mutation in the Catalytic Domain that Reduces Tissue Factor Binding, Impairs Activation by Factor XA, and Abolishes Amidolytic and Coagulant Activity,”J. Biological Chemistry271(48):30685-30691 (1996).
Bjoern, S., et al., “Human Plasma and Recombinant Factor VII—Characterization ofO-Glycosylations at Serine Residues 52 and 60 and Effects of Site-Directed Mutagenesis of Serine 52 to Alanine,”J. Biological Chemistry266(17):11051-11057 (1991).
Chang, J-Y., et al., “Replacing the First Epidermal Growth Factor-like Domain of Factor IX with That of Factor VII Enhances Activity In Vitro and in Canine Hemophilia B,”J. Clin. Invest. 100(4):886-892 (1997).
Chang, Y-J., et al., “Engineered Recombinant Factor VII Q217Variants with Altered Inhibitor Specificities,”Biochemistry38: 10940-10948 (1999).
Kemball-Cook, G., et al., “Coagulation Factor VII Gln100→Arg—Amino Acid Substitution at the Epidermal Growth Factor 2-Protease Domain Interface Results in Severely Reduced Tissue Factor Binding and Procoagulant Function,”J. Biological Chemistry273(14):8516-8521 (1998).
Dickinson, C.D., et al., “Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tiss
Andersen Kim Vilbour
Bornaes Claus
Pedersen Anders Hjelholt
Kruse Norman J.
Maxygen Holdings Ltd.
Petithory Joanne R.
Powers Margaret A.
Tate Christopher
LandOfFree
Factor VII or VIIa-like molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Factor VII or VIIa-like molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor VII or VIIa-like molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3994664